CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
Completed · Phase 1/Phase 2
Conditions studied: Kidney Transplantation
In brief
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.
Key facts
- Study ID
- NCT02217410
- Run by
- Novartis Pharmaceuticals
- People needed
- 59
- Starts
- 2015-02-05
- Expected to finish
- 2017-11-29
- Last updated by the study team
- 2021-09-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Aurora, Colorado, United States
- Novartis Investigative Site — Baltimore, Maryland, United States
- Novartis Investigative Site — Ann Arbor, Michigan, United States
- Novartis Investigative Site — Detroit, Michigan, United States
- Novartis Investigative Site — Livingston, New Jersey, United States
- Novartis Investigative Site — Cincinnati, Ohio, United States
- Novartis Investigative Site — São Paulo, São Paulo, Brazil
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Heidelberg, Germany
- Novartis Investigative Site — Utrecht, The Netherlands, Netherlands
- Novartis Investigative Site — Groningen, Netherlands
- Novartis Investigative Site — Rotterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.